/

ELDN

Eledon Pharmaceuticals, Inc.Pre-market

2.34−0.10 −4.10%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 2.36 +0.86%

Open

2.49

Prev close

2.44

Day range

2.322.49

52-week range

1.354.60

Volume

1.17M1.27×

Mkt cap

190.15M

P/E ttm

—

Fwd P/E

-3.04

EPS ttm

-0.9000

Div yield

0.00%

Earnings

—

From 52w high

−49.13%

Price Chart

Yahoo Finance · delayed

ELDNOct 13, 2026O 2.49H 2.49L 2.32C 2.34−0.10 (−4.10%)Vol 1.17M

SMA 503.00
SMA 2003.06

1Y change −13.97% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ELDN Eledon Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.49%
1 month: −15.83%
3 months: −42.22%
6 months: −26.88%
Year to date: +54.97%
1 year: −13.97%

Valuation & ownership

Market cap: 190.15M
Enterprise value: 101.86M
P/E (ttm): —
Forward P/E: -3.04
PEG ratio: —
Price / book: 2.63
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.9000
EPS (forward): -0.7700
Beta (5y monthly): 0.85
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 81.26M
Float: 74.60M
Short % of float: 9.66%
Short ratio (days): 8.20
Held by insiders: 0.33%
Held by institutions: 58.64%
Avg volume (3m): 916.88K
50-day average: 3.02
200-day average: 3.06
52-week change: −13.97%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.5
vs 50-day SMA: −21.96%
vs 200-day SMA: −23.57%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.27%
Realised vol (20d, ann.): 48.1%
From 52-week high: −49.13%
From 52-week low: +73.33%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

9.00

+284.62% implied

Low 7.00Median 8.00High 12.00

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0

Buy / hold / sell counts

DES

About Eledon Pharmaceuticals, Inc.

Yahoo Finance profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 33
Headquarters: Irvine, CA, United States
Website: eledon.com
Officers: Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director
Mr. Paul Sean Little Chief Financial Officer

SEAS

Seasonality · ELDN

2014–2026 · monthly returns

Strongest month Jan +13.96%Weakest month Jun −18.30%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	45.7	19.1	17.6	18.2	4.7	3.4	-14.2	-11.8	-15.1	-7.5			+55.0%
2025	9.7	-8.2	-18.3	-6.8	-5.1	-9.7	16.2	-17.8	0.0	66.8	-62.3	-7.4	−63.3%
2024	-1.1	1.1	14.4	16.0	15.1	-4.0	11.4	-4.4	-11.4	86.7	0.2	-11.6	+128.9%
2023	45.6	-28.9	0.0	-11.0	0.0	-34.8	0.7	10.1	-9.9	13.9	-26.3	56.5	−21.1%
2022	-8.2	-12.8	11.6	-22.3	4.2	-23.5	23.4	24.6	-26.4	-12.7	1.2	-6.6	−48.3%
2021	-3.7	8.4	-33.4	-6.5	-4.8	-16.9	-18.0	28.2	-25.7	-19.1	-2.2	-9.8	−71.4%
2020	1.6	-4.9	-30.4	77.7	83.3	-63.9	-0.7	-7.5	125.7	53.1	-6.7	-36.9	+47.5%
2019	168.8	12.3	-16.8	-34.1	-35.1	-41.3	-16.5	-13.4	-15.1	0.0	6.9	-12.5	−63.8%
2018	-10.3	0.8	37.3	-12.5	85.5	-14.4	4.7	-35.2	-1.7	-28.1	3.3	-53.9	−60.6%
2017	-3.8	-12.9	2.0	-26.8	-7.0	14.3	-31.5	-1.2	31.6	-27.4	9.8	-2.2	−53.9%
2016	-28.1	1.6	-11.9	30.7	-1.1	-24.0	-77.1	-12.7	39.1	-28.1	-6.4	-5.0	−88.8%
2015	-16.8	23.4	-25.3	-11.5	13.7	17.0	-2.0	-9.4	-12.4	6.8	4.1	-24.2	−40.8%
2014										1.8	-4.9	0.5	−2.6%

INSD

Insider Activity · ELDN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 30, 2026	Gros David-Alexandre CChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	354.5K	—
Jul 30, 2026	Perrin StevenPresident	Stock Award(Grant) at price 0.00 per share.	152.4K	—
Jan 8, 2026	Katkin Keith ADirector	—	8.6K	—
Jan 8, 2026	Mcbride John SDirector	—	3.4K	—
Jan 8, 2026	Lee June YongDirector	—	3.4K	—
Jan 8, 2026	Robinson James A Jr.Director	—	3.4K	—
Jan 8, 2026	Hillson Jan M.D. Ph.D.Director	—	3.4K	—
Jan 8, 2026	Kirk AllanDirector	—	3.4K	—

13F

Investors Holding ELDN

latest 13F filings of 29 followed managers

Investors holding ELDN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$791.5K	0.00%	200.90K	+717%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ELDN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ELDN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Eledon Pharmaceuticals, Inc.

Seasonality · ELDN

Insider Activity · ELDN

Congress Trades · ELDN

Investors Holding ELDN

Investors Holding ELDN

Congress Trades · ELDN

Insider Activity · ELDN

Seasonality · ELDN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Eledon Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News